

# Nicole A Shonka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6311066/publications.pdf>

Version: 2024-02-01

42  
papers

908  
citations

840776

11  
h-index

477307

29  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1960  
citing authors

#	ARTICLE	IF	CITATIONS
1	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. <i>Neuro-Oncology</i> , 2014, 16, 81-91.	1.2	370
2	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. <i>Journal of Neuro-Oncology</i> , 2019, 145, 97-105.	2.9	125
3	Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 266.	8.6	81
4	Natural products: a hope for glioblastoma patients. <i>Oncotarget</i> , 2018, 9, 22194-22219.	1.8	77
5	Atypical Teratoid/Rhabdoid Tumors in Adults: A Case Report and Treatment-Focused Review. <i>Journal of Clinical Medicine Research</i> , 2011, 3, 85-92.	1.2	33
6	Targeted Treatment of Brain Metastases. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 37.	4.2	28
7	Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. <i>Journal of Neuro-Oncology</i> , 2013, 113, 305-311.	2.9	24
8	EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 170-179.	4.4	18
9	Post-operative perfusion and diffusion MR imaging and tumor progression in high-grade gliomas. <i>PLoS ONE</i> , 2019, 14, e0213905.	2.5	15
10	Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells. <i>Carcinogenesis</i> , 2019, 40, 2-14.	2.8	12
11	Targets for therapy in ependymoma. <i>Targeted Oncology</i> , 2011, 6, 163-169.	3.6	11
12	Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. <i>Targeted Oncology</i> , 2013, 8, 117-125.	3.6	10
13	Undifferentiated Embryonal Sarcoma of Liver. <i>Rare Tumors</i> , 2015, 7, 130-132.	0.6	10
14	PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. <i>Anticancer Research</i> , 2015, 35, 5467-72.	1.1	10
15	Safety of long-term anticoagulation in patients with brain metastases. <i>Medical Oncology</i> , 2018, 35, 43.	2.5	9
16	Intrathecal Interleukin-2 for Melanomatous Meningitis. <i>Journal of Clinical Oncology</i> , 2014, 32, e111-e113.	1.6	8
17	Seizure prevalence, contributing factors, and prognostic factors in patients with leptomeningeal disease. <i>Journal of the Neurological Sciences</i> , 2019, 403, 19-23.	0.6	8
18	Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 335.	8.6	8

#	ARTICLE	IF	CITATIONS
19	Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.. Journal of Clinical Oncology, 2020, 38, 3615-3615.	1.6	8
20	Evaluating the decisions of glioma patients regarding clinical trial participation: a retrospective single provider review. Medical Oncology, 2019, 36, 34.	2.5	6
21	Biomarkers for glioblastoma: MMP2 and NGAL.. Journal of Clinical Oncology, 2016, 34, e13516-e13516.	1.6	6
22	Highly Aggressive and Radiation-Resistant, "Atypical" and Silent Pituitary Corticotrophic Carcinoma: A Case Report and Review of the Literature. Case Reports in Oncology, 2019, 12, 139-146.	0.7	4
23	Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a review of treatment and the integration of molecular markers. Oncology, 2012, 26, 1083-91.	0.5	4
24	ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. Neuro-Oncology, 2018, 20, vi19-vi19.	1.2	3
25	Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.. Journal of Clinical Oncology, 2019, 37, 3005-3005.	1.6	3
26	Near Misdiagnosis of Glioblastoma as Primary Central Nervous System Lymphoma. Journal of Clinical Medicine Research, 2014, 6, 299-301.	1.2	3
27	PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2019, 21, vi186-vi186.	1.2	2
28	Primary clear cell sarcoma in the lung apex with spinal metastasis: a fatal outcome. BMJ Case Reports, 2020, 13, e231556.	0.5	2
29	Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.. Journal of Clinical Oncology, 2020, 38, 3617-3617.	1.6	2
30	HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2020, 22, iii347-iii347.	1.2	2
31	ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2019, 21, vi20-vi21.	1.2	1
32	Efficacy of sequential radiation and chemotherapy in treating glioblastoma with poor performance status. Journal of Neuro-Oncology, 2020, 147, 91-95.	2.9	1
33	High-Dose Therapy (HDT) with Hematopoietic Stem Cell Transplantation (HSCT) Is Effective Therapy for Patients with Non-Hodgkin Lymphoma (NHL) and Central Nervous System (CNS) Involvement. Blood, 2010, 116, 1358-1358.	1.4	1
34	Complications of anticoagulant therapy in patients with brain metastases.. Journal of Clinical Oncology, 2016, 34, 2078-2078.	1.6	1
35	Integrated clinical experience with ONC201 in H3 K27M glioma.. Journal of Clinical Oncology, 2018, 36, 2059-2059.	1.6	1
36	CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 2020, 22, ii50-ii51.	1.2	1

#	ARTICLE	IF	CITATIONS
37	Searching for Synergy: Combining Drugs and Stereotactic Radiosurgery for the Treatment of Brain Metastases. <i>Journal of Oncology Practice</i> , 2016, 12, 713-714.	2.5	0
38	NCMP-25. SEIZURE INCIDENCE AND CONTRIBUTING FACTORS IN PATIENTS WITH LEPTOMENINGEAL DISEASE. <i>Neuro-Oncology</i> , 2018, 20, vi199-vi199.	1.2	0
39	INNV-46. EVALUATING THE DECISIONS OF GLIOMA PATIENTS REGARDING CLINICAL TRIAL PARTICIPATION, A RETROSPECTIVE SINGLE PROVIDER STUDY. <i>Neuro-Oncology</i> , 2018, 20, vi147-vi147.	1.2	0
40	Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging. <i>PLoS ONE</i> , 2021, 16, e0244275.	2.5	0
41	PC or PCV? That is the question: A retrospective review of primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU without or with vincristine.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2046-2046.	1.6	0
42	CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii45-ii46.	1.2	0